ERBB2 and Hand-foot syndrome: Thus, 60 mg/m2 was established as D RD in combination with T. Among HER2-negative patients, DLT, represented by G3 hand-foot syndrome (HFS), occurred in 1 out of 3 patients enrolled in the first cohort at D 65 mg/m2, so a new cohort was enrolled at the same dose-level and 1 DLT, represented by G2 anemia for more than 2 weeks, occurred.